Shares of Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report) traded up 11.3% during trading on Wednesday. The stock traded as high as $4.09 and last traded at $4.2730. 260,194 shares changed hands during trading, a decline of 92% from the average daily volume of 3,383,160 shares. The stock had previously closed at $3.84.
Key Headlines Impacting Prime Medicine
These are some of the PRME headlines that stood out recently:
- Positive Sentiment: HC Wainwright raised its EPS estimates for multiple periods, including FY2026 to a loss of $0.99 per share from $1.11, and FY2027 to a loss of $0.89 from $0.91. The firm maintained its Buy rating and $8 price target. Prime Medicine coverage
- Positive Sentiment: HC Wainwright’s Buy rating was also reaffirmed, providing continued analyst support for PRME. Prime Medicine rating reaffirmed
- Neutral Sentiment: Prime Medicine presented at the Jefferies Global Healthcare Conference; the supplied article entry does not describe specific announcements or new data. Jefferies conference transcript
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Prime Medicine in a report on Monday, August 31st. BMO Capital Markets initiated coverage on Prime Medicine in a report on Tuesday, August 18th. They set an "outperform" rating and a $9.00 price target on the stock. Jefferies Financial Group restated a "market outperform" rating on shares of Prime Medicine in a research report on Monday, September 28th. Chardan Capital reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Prime Medicine in a research note on Friday, September 25th. Finally, Wall Street Zen upgraded Prime Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Prime Medicine has an average rating of "Moderate Buy" and a consensus target price of $7.86.
Get Our Latest Research Report on PRME
Prime Medicine Trading Up 2.7%
The business has a 50-day moving average price of $3.71 and a 200 day moving average price of $3.51. The stock has a market capitalization of $717.67 million, a P/E ratio of -4.09 and a beta of 2.14.
Prime Medicine (NASDAQ:PRME - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. The company had revenue of $4.21 million for the quarter. On average, sell-side analysts predict that Prime Medicine, Inc. will post -0.97 earnings per share for the current fiscal year.
Institutional Trading of Prime Medicine
Several hedge funds have recently made changes to their positions in PRME. Aquatic Capital Management LLC bought a new position in Prime Medicine during the third quarter valued at $43,000. Marshall Wace LLP lifted its holdings in shares of Prime Medicine by 225.7% in the 3rd quarter. Marshall Wace LLP now owns 706,281 shares of the company's stock worth $2,161,000 after acquiring an additional 489,440 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Prime Medicine during the 3rd quarter worth about $150,000. Palumbo Wealth Management LLC boosted its stake in shares of Prime Medicine by 52.2% during the 3rd quarter. Palumbo Wealth Management LLC now owns 157,962 shares of the company's stock worth $483,000 after purchasing an additional 54,161 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Prime Medicine by 244.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 175,500 shares of the company's stock valued at $536,000 after purchasing an additional 124,506 shares during the last quarter. 70.37% of the stock is currently owned by hedge funds and other institutional investors.
Prime Medicine Company Profile
(
Get Free Report)
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prime Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.
While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.